Total Artificial Heart Implantation Blood Pressure Management as Resolving Treatment for Massive Hemolysis following Total Artificial Heart Implantation
DOI:
https://doi.org/10.1532/hsf.1633Abstract
The SynCardia Total Artificial Heart (TAH) has been used for patients with biventricular failure, who cannot be managed with implantation of a left ventricular (LV) assist device. Following TAH implantation, our patient developed severe hemolysis, which could only be managed successfully by aggressive blood pressure control [Ohashi 2003; Nakata 1998].References
Nakata Ki, Ohashi Y, Muller J, Gleuck J, Nose Y. 1998. Assessment of the total artificial heart (TAH) pulsatility: the coalition between pulsatility and ejection time in TAH in vitro study. Ann Thorac Cardiovasc Surg 4:275-9.
Ohashi Y, de Andrade A, Nosé Y. 2003. Hemolysis in an electromechanical driven pulsatile total artificial heart. Artif Organs 27:1089-93.
Published
2016-10-21
How to Cite
Ghodsizad, A., Koerner, M. M., El-Banayosy, A., Zeriouh, M., Ruhparwar, A., & Loebe, M. (2016). Total Artificial Heart Implantation Blood Pressure Management as Resolving Treatment for Massive Hemolysis following Total Artificial Heart Implantation. The Heart Surgery Forum, 19(5), E229. https://doi.org/10.1532/hsf.1633
Issue
Section
Articles